FDA Clears Meridian's C. difficile Test for Pediatric Patients | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration has cleared its illumigene C. difficile test for pediatric use.

The test is based on Meridian's loop amplification technology, which is isothermal and requires no costly capital equipment, and targets the region of the C. difficile DNA present in all toxin A and/or toxin B producing strains.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.